Skip to Content

Tagitol V Suspension

Generic Name: barium sulfate
Dosage Form: suspension

Medically reviewed on Oct 1, 2018

1  INDICATIONS AND USAGE

TAGITOL V is indicated for use in adult patients for use in computed tomography (CT) colonography as a fecal tagging agent.

2  DOSAGE AND ADMINISTRATION

Recommended Dosing

  • The recommended oral dose of TAGITOL V is one 20 mL bottle (8 g barium sulfate) with each meal (breakfast, lunch and dinner) the day before the colonography examination. Total dose = 3 bottles (24 g barium sulfate).

Important Administration Instructions

  • TAGITOL V is typically provided to the patient for self-administration. Advise patients to carefully read and follow the Patient Instructions for Use to be provided to the patient.
  • Shake bottle for 15 seconds prior to administration.
  • For oral use only.
  • Encourage patients to hydrate following the barium sulfate procedure.
  • Discard any unused suspension.

3  DOSAGE FORMS AND STRENGTHS

Oral suspension: barium sulfate (40% w/v) supplied as a ready-to-use suspension in a 20 mL, single-dose, plastic bottle for oral administration. Each 20 mL bottle contains 8 g of barium sulfate.

4  CONTRAINDICATIONS

TAGITOL V is contraindicated in patients with:

   -   known or suspected perforation of the gastrointestinal (GI) tract;

   -   known obstruction of the GI tract;

   -   high risk of GI perforation such as those with a recent GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to the pelvis;

   -   high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation;

   -   known hypersensitivity to barium sulfate or any of the excipients of TAGITOL V.

5  WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Barium sulfate preparations contain a number of excipients, including natural and artificial flavors and may induce serious hypersensitivity reactions. The manifestations include hypotension, bronchospasm and other respiratory impairments, dermal reactions including rashes, urticaria and itching. A history of bronchial asthma, atopy, or a previous reaction to a contrast agent may increase the risk for hypersensitivity reactions. Emergency equipment and trained personnel should be immediately available for treatment of a hypersensitivity reaction.

Intra-abdominal Barium Leakage

The use of TAGITOL V is contraindicated in patients at high risk of perforation of the GI tract [see Contraindications (4)]. Administration of TAGITOL V may result in leakage of barium from the GI tract in the presence of conditions that increase the risk of perforation such as carcinomas, GI fistula, inflammatory bowel disease, gastric or duodenal ulcer, appendicitis, or diverticulitis, and in patients with a severe stenosis at any level of the gastrointestinal tract, especially if it is distal to the stomach. The barium leakage has been associated with peritonitis and granuloma formation.

Delayed Gastrointestinal Transit and Obstruction

Orally administered barium sulfate may accumulate proximal to a constricting lesion of the colon, causing obstruction or impaction with development of baroliths (inspissated barium associated with feces) and may lead to abdominal pain, appendicitis, bowel obstruction, or rarely perforation. Patients with the following conditions are at higher risk for developing obstruction or baroliths: severe stenosis at any level of the GI tract, impaired gastrointestinal motility, electrolyte imbalance, dehydration, on a low residue diet, on medications that delay GI motility, constipation, cystic fibrosis, Hirschsprung disease, and the elderly. To reduce the risk of delayed GI transit and obstruction, patients should maintain adequate hydration following a barium sulfate procedure.

Aspiration Pneumonitis

The use of TAGITOL V is contraindicated in patients at high risk of aspiration [see Contraindications (4)]. Oral administration of barium is associated with aspiration pneumonitis, especially in patients with a history of food aspiration or with compromised swallowing mechanism. Vomiting following oral administration of barium sulfate may lead to aspiration pneumonitis.

Systemic Embolization

Barium sulfate products may occasionally intravasate into the venous drainage of the large bowel and enter the circulation as a "barium embolus" leading to potentially fatal complications which include systemic and pulmonary embolism, disseminated intravascular coagulation, septicemia and prolonged severe hypotension. Although this complication is exceedingly uncommon after oral administration of barium sulfate products, monitor patients for potential intravasation when administering barium sulfate.

6  ADVERSE REACTIONS

The following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:

  • Nausea, vomiting, diarrhea and abdominal cramping
  • Serious adverse reactions and fatalities include aspiration pneumonitis, barium sulfate impaction, intestinal perforation with consequent peritonitis and granuloma formation, vasovagal and syncopal episodes.

8  USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

TAGITOLVis not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see Clinical Pharmacology (12.3)].

Lactation

Risk Summary

TAGITOL V is not absorbed systemically by the mother following oral administration and breastfeeding is not expected to result in exposure of the infant to the drug [see Clinical Pharmacology (12.3)]

Pediatric Use

TAGITOL V is not indicated for pediatric use.

Geriatric Use

Clinical studies of TAGITOL V do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

11  DESCRIPTION

TAGITOL V (barium sulfate) is a radiographic contrast agent that is supplied as a 40% w/v, off-white to lightly colored, free-flowing, ready-to-use suspension with an apple aroma for oral administration. The active ingredient barium sulfate is designated chemically as BaSO4 with a molecular weight of 233.4 g/mol and the following chemical structure:

TAGITOL V contains the following excipients: carboxymethylcellulose sodium, citric acid, glycerin, maltodextrin, natural and artificial apple flavor, polysorbate 80, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, xanthan gum, and xylitol.

12  CLINICAL PHARMACOLOGY

Mechanism of Action

Due to its high atomic number, barium (the active ingredient in TAGITOL V) is opaque to x-rays and therefore acts as a positive contrast agent for radiographic studies.

Pharmacodynamics

Barium sulfate is biologically inert and has no known pharmacological effects.

Pharmacokinetics

Under physiological conditions, barium sulfate passes through the gastrointestinal tract in an unchanged form and is absorbed only in pharmacologically insignificant amounts.

13  NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal studies have been performed to evaluate the carcinogenic potential of barium sulfate or potential effects on fertility.

16  HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

TAGITOL V (barium sulfate) is an oral suspension (40% w/v) supplied as a box of three 20 mL HDPE bottles. Each bottle contains 8 grams barium sulfate.

Provided as: 24 boxes, each containing 3 (20 mL) bottles (NDC 32909-814)

Storage and Handling

Store at USP controlled room temperature 20 to 25°C (68 to 77° F). Protect from freezing.

17  PATIENT COUNSELING INFORMATION

After administration, advise patients to:

  • Maintain adequate hydration [see Dosage and Administration (2.2) and Warnings and Precautions (5.3)].
  • Seek medical attention for worsening of constipation or slow gastrointestinal passage [see Warnings and Precautions (5.3)].
  • Seek medical attention for any delayed onset of hypersensitivity: rash, urticaria, or respiratory difficulty [see Warnings and Precautions (5.1)].

Administration Instructions

TAGITOL V is typically provided to the patient for self-administration. Advise patients to carefully read and follow the Patient Instructions for Use to be provided to the patient.

Provide the patient with any site specific instructions regarding their procedure and when to take meals.


Rx only

Manufactured by
EZEM Canada Inc
Anjou (Quebec) Canada H1J 2Z4
For
Bracco Diagnostics Inc.
Monroe Township, NJ 08831

INSTRUCTIONS FOR USE

TAGITOL V (tag-i-täl vē)

(barium sulfate)

oral suspension

Read this Instructions for Use before you drink TAGITOL V (barium sulfate) oral suspension. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Important:

Take TAGITOL V exactly as your healthcare provider tells you. Your healthcare provider will prescribe the dose that is right for you. You can ask your healthcare provider or pharmacist if you have any questions about how to take TAGITOL V.

How should I store TAGITOL V?

  • Before using TAGITOL V store at room temperature between 68°F and 77°F (20°C and 25°C).
  • Do not freeze.

Keep TAGITOL V and all medicines out of the reach of children.

Supplies you will need:

  • 1 box containing 3 bottles of TAGITOL V. Each bottle contains 20 mL of TAGITOL V

How should I take TAGITOL V

The day before your procedure you will drink 1 bottle of TAGITOL V with each meal:

  • Breakfast: Shake 1 bottle of TAGITOL V for 15 seconds, open the bottle, and drink the liquid with breakfast.
  • Lunch: Shake 1 bottle of TAGITOL V for 15 seconds, open the bottle, and drink the liquid with lunch.
  • Dinner: Shake 1 bottle of TAGITOL V for 15 seconds, open the bottle, and drink the liquid with dinner.

Throw away any unused TAGITOL V with normal household trash. Do not throw away by flushing down the drain.

What should I do if the TAGITOL V spills?

If you spill the liquid while shaking or drinking it, you can clean it up. TAGITOL V is not harmful and can be thrown away with normal household trash.

If you spilled any of the liquid, check with your healthcare provider to find out if you need to change the date of the appointment for your procedure.

This Instructions for Use has been approved by the U.S. Food and Drug Administration

Approved: August 2017

Tagitol V Internal Label

Tagitol V External Label

Tagitol V Carton
NDC: 32909-814-53

TAGITOL V 
barium sulfate suspension
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:32909-814
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Barium Sulfate (Barium Sulfate) Barium Sulfate 400 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
anhydrous citric acid  
dimethicone 350  
dimethicone 1000  
glycerin  
maltodextrin  
polysorbate 80  
potassium sorbate  
saccharin sodium  
silicon dioxide  
sodium benzoate  
trisodium citrate dihydrate  
water  
xanthan gum  
xylitol  
CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM  
Product Characteristics
Color WHITE Score     
Shape Size
Flavor APPLE Imprint Code
Contains     
Packaging
# Item Code Package Description
1 NDC:32909-814-53 24 BOX in 1 CASE
1 3 BOTTLE, PLASTIC in 1 BOX
1 20 mL in 1 BOTTLE, PLASTIC
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA208143 08/04/2017
Labeler - E-Z-EM Canada Inc (204211163)
Registrant - E-Z-EM, INC. (002041226)
 
E-Z-EM Canada Inc
Hide